Kozłowska Hanna, Szymska Urszula, Schlicker Eberhard, Malinowska Barbara
Zakład Fizjologii Doświadczalnej, Akademia Medyczna w Białymstoku, ul. Mickiewicza 2A, 15-089 Białystok, Poland.
Br J Pharmacol. 2003 Sep;140(1):3-12. doi: 10.1038/sj.bjp.0705421. Epub 2003 Aug 4.
(1) We examined whether beta3- and/or atypical beta-adrenoceptors relax the rat isolated mesenteric artery. (2) Mesenteric arteries precontracted with phenylephrine were relaxed by beta-agonists with the following potencies (pD2): nonselective agonist isoprenaline (6.00)>nonconventional partial agonist cyanopindolol (5.45)>beta2-agonist fenoterol (4.98)>nonconventional partial agonist CGP 12177 (4.19)>beta3-agonist ZD 2079 (3.72). The beta3-agonist CL 316243 1 mm relaxed the vessel only marginally. (3) The concentration-response curves (CRCs) for cyanopindolol, CGP 12177 and ZD 2079 were not affected by the nonselective beta-antagonist propranolol 0.3 microm, the beta2-antagonist ICI 118551 1 microm and by CL 316243 60 microm, but shifted to the right by bupranolol (pA2 5.3-5.7), CGP 20712 (5.4) and SR 59230A (6.5-6.7) (the latter three drugs block atypical and/or beta3-adrenoceptors at high concentrations). (4) The CRC for isoprenaline was shifted to the right by propranolol (pA2 7.0) but, in the presence of propranolol 0.3 microm, not affected by SR 59230A 1 microm. The CRC for fenoterol was shifted to the right by propranolol (pA2 6.9) and ICI 118551 (6.8). (5) Removal of endothelium diminished the vasorelaxant effects of cyanopindolol, CGP 12177 and ZD 2079. (6) Fenoterol and cyanopindolol also relaxed (endothelium-intact) mesenteric arteries precontracted with serotonin. The relaxant effect of cyanopindolol was antagonized by bupranolol to about the same degree as in phenylephrine-contracted vessels. (7) In conclusion, beta2- and atypical beta-adrenoceptors (but not beta3-adrenoceptors) relax the rat mesenteric artery. The atypical beta-adrenoceptor, which is partially located endothelially, may differ from the low-affinity state of the beta1-adrenoceptor.
(1) 我们研究了β3 - 和/或非典型β - 肾上腺素能受体是否能使大鼠离体肠系膜动脉舒张。(2) 用去氧肾上腺素预收缩的肠系膜动脉可被β - 激动剂舒张,其效能(pD2)如下:非选择性激动剂异丙肾上腺素(6.00)>非常规部分激动剂氰吲哚洛尔(5.45)>β2 - 激动剂非诺特罗(4.98)>非常规部分激动剂CGP 12177(4.19)>β3 - 激动剂ZD 2079(3.72)。β3 - 激动剂CL 316243 1 mmol/L仅使血管稍有舒张。(3) 氰吲哚洛尔、CGP 12177和ZD 2079的浓度 - 反应曲线(CRCs)不受非选择性β - 拮抗剂普萘洛尔0.3 μmol/L、β2 - 拮抗剂ICI 118551 1 μmol/L和CL 316243 60 μmol/L的影响,但被布普洛尔(pA2 5.3 - 5.7)、CGP 20712(5.4)和SR 59230A(6.5 - 6.7)(后三种药物在高浓度时阻断非典型和/或β3 - 肾上腺素能受体)右移。(4) 异丙肾上腺素的CRCs被普萘洛尔(pA2 7.0)右移,但在存在0.3 μmol/L普萘洛尔时,不受1 μmol/L SR 59230A的影响。非诺特罗的CRCs被普萘洛尔(pA2 6.9)和ICI 118551(6.8)右移。(5) 去除内皮可减弱氰吲哚洛尔、CGP 12177和ZD 2079的血管舒张作用。(6) 非诺特罗和氰吲哚洛尔也能使用5 - 羟色胺预收缩的(内皮完整)肠系膜动脉舒张。氰吲哚洛尔的舒张作用被布普洛尔拮抗的程度与在去氧肾上腺素收缩的血管中大致相同。(7) 总之,β2 - 和非典型β - 肾上腺素能受体(而非β3 - 肾上腺素能受体)使大鼠肠系膜动脉舒张。部分位于内皮的非典型β - 肾上腺素能受体可能与β1 - 肾上腺素能受体的低亲和力状态不同。